Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Profit After Tax for 12 consecutive years, with -$96.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 15.5% year-over-year to -$96.2 million; the TTM figure through Mar 2026 stood at -$395.0 million (up 24.68% YoY), while the FY2025 annual figure was -$412.7 million, up 20.49% from the prior year.
• Profit After Tax steadied at -$96.2 million in Q1 2026 per NTLA's latest filing, from -$96.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$96.2 million in Q4 2025 and bottomed at -$147.0 million in Q2 2024.
• Historically, Profit After Tax has averaged -$116.5 million across 5 years, with a median of -$113.4 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax tumbled 217.87% — and 2025, when it soared 31.11%.
• Intellia Therapeutics' Profit After Tax stood at -$113.4 million in 2022, then decreased by 15.38% to -$130.8 million in 2023, then decreased by 1.13% to -$132.3 million in 2024, then increased by 27.32% to -$96.2 million in 2025, then dropped by 0.06% to -$96.2 million in 2026.
• Business Quant data shows NTLA's Profit After Tax at -$96.2 million in Q1 2026, -$96.2 million in Q4 2025, and -$101.3 million in Q3 2025.